Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05672199
Other study ID # 20210210
Secondary ID 2022-001686-12
Status Recruiting
Phase Phase 2
First received
Last updated
Start date April 28, 2023
Est. completion date January 27, 2028

Study information

Verified date June 2024
Source Amgen
Contact Amgen Call Center
Phone 866-572-6436
Email medinfo@amgen.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of this study is to evaluate the long-term safety and tolerability of efavaleukin alfa in participants with moderate to severe ulcerative colitis (UC).


Recruitment information / eligibility

Status Recruiting
Enrollment 140
Est. completion date January 27, 2028
Est. primary completion date January 27, 2028
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Participant has provided informed consent prior to initiation of any study specific activities/procedures. - Participant has completed the week 52 endoscopy in the phase 2 dose-finding parent study (20170104) and who in the opinion of the investigator may benefit from continued treatment. Exclusion criteria: - Permanent discontinuation of investigational product during the 52- week phase 2 dose finding parent study (20170104) for any reason - Female subjects of reproductive potential must agree not to donate eggs during the study and for 6 weeks after receiving the last dose of investigational product. Disease Related: - Adenoma and dysplasia exclusion criteria: - Any current sporadic adenoma without dysplasia (adenomatous polyps occurring proximal to known areas of colitis) that has not been removed. - Dysplasia occurring in flat mucosa, sporadic adenomas containing dysplasia, and dysplasia-associated lesions or masses will be managed as follows: - Any history or current evidence of high-grade dysplasia. - Any history or current evidence of dysplasia occurring in flat mucosa. - This includes histopathology reporting indefinite for dysplasia, low-grade dysplasia, and high-grade dysplasia. - Any history or current evidence of a nonadenoma like dysplasia associated lesions or masses, with or without evidence of dysplasia. - Any current sporadic adenoma containing dysplasia or any current adenoma-like dysplasia-associated lesions or masses that has not been removed. Other Medical Conditions: - Any malignancy diagnosed during parent Study 20170104, including evidence of cutaneous basal or squamous cell carcinoma or melanoma - Active infection (including chronic, acute, recurrent, opportunistic infections) at the time of eligibility evaluation requiring intravenous (IV) anti-infectives or hospitalization (infections requiring oral and/or topical anti-infective[s] for > 7 days may be allowed in consultation with the Amgen physician). - Required systemic corticosteroid use for any indication other than ulcerative colitis. The only exception is corticosteroids used for the treatment of adrenal insufficiency are allowed. - Plan to receive a live (attenuated) vaccine during the treatment period and up to 6 weeks after the last dose of investigational product in the long term extension study. Prior/Concurrent Clinical Study Experience: - Currently receiving treatment in another investigational device or drug study. Other investigational procedures while participating in this study are excluded. Other Exclusions: - Female participants who are pregnant or breastfeeding or planning to become pregnant or breastfeed during study and for an additional 6 weeks after the last dose of investigational product. - Female participants of childbearing potential unwilling to use protocol specified method of contraception see Appendix 5 (Section 11.5) during treatment and for an additional 6 weeks after the last dose of investigational product. - Participant has known sensitivity to any of the products to be administered during dosing with the exception of participants who exhibited sensitivity in parent Study 20170104 but did not result in treatment discontinuation. - Participant likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures (e.g., Clinical Outcome Assessments) to the best of the participant and investigator's knowledge. - Participant has a history or evidence of any other clinically significant disorder (including laboratory abnormalities), condition, or disease that, in the opinion of the investigator or Amgen physician, if consulted would pose a risk to participant safety, or interfere with the study evaluation, procedures, or completion.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Efavaleukin alfa
Subcutaneous (SC) injection
Placebo
SC injection

Locations

Country Name City State
Argentina Centro de Investigaciones Medicas Mar del Plata Mar del Plata Buenos Aires
Argentina Clinica Independencia Munro Buenos Aires
Argentina Cer Instituto Medico Quilmes Buenos Aires
Bulgaria Diagnostic-Consultative Center Convex EOOD Sofia
Denmark Herlev Hospital Herlev
Germany Universitaetsklinikum Ulm Ulm
Hungary Clinexpert Kft Budapest
Hungary MIND Klinika Kft Budapest
Hungary Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont Altalanos Orvostudomanyi Kar Szeged
Japan Tsujinaka Hospital Kashiwanoha Kashiwa-shi Chiba
Japan Nagasaki University Hospital Nagasaki-shi Nagasaki
Korea, Republic of Wonju Severance Christian Hospital Wonju-si, Gangwon-do
Mexico Clinica de Investigacion en Reumatologia y Obesidad SC Guadalajra Jalisco
Poland NZOZ Twoje Zdrowie EL Spzoo Elblag
Poland Centrum Medyczne Melita Medical Wroclaw-Krzyki
Romania Clinica Medicum Bucuresti
Romania Spitalul Clinic Colentina Bucuresti
Romania Spitalul de Oncologie Monza SRL Bucuresti
Switzerland Intesto BE Bern
Turkey Kocaeli Universitesi Tip Fakultesi Hastanesi Kocaeli
Turkey Mersin Universitesi Tip Fakultesi Hastanesi Mersin
United States University of Kansas Medical Center Kansas City Kansas
United States Indian Health Service Health Research Kissimmee Florida
United States Santa Maria Gastroenterology Medical Group Santa Maria California

Sponsors (1)

Lead Sponsor Collaborator
Amgen

Countries where clinical trial is conducted

United States,  Argentina,  Bulgaria,  Denmark,  Germany,  Hungary,  Japan,  Korea, Republic of,  Mexico,  Poland,  Romania,  Switzerland,  Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants with Treatment-emergent Adverse Events (TEAEs) Day 1 to Week 110
Secondary Number of Participants with Clinical Response at Week 52 Week 52
Secondary Number of Participants with Clinical Response at Week 104 Week 104
Secondary Number of Participants with Clinical Remission at Week 52 Week 52
Secondary Number of Participants with Clinical Remission at Week 104 Week 104
Secondary Number of Participants with Durable Clinical Remission at Week 52 Week 52
Secondary Number of Participants with Durable Clinical Remission at Week 104 Week 104
Secondary Number of Participants with Endoscopic Remission at Week 52 Week 52
Secondary Number of Participants with Endoscopic Remission at Week 104 Week 104
Secondary Number of Participants with Histologic Remission at Week 52 Week 52
Secondary Number of Participants with Histologic Remission at Week 104 Week 104
Secondary Number of Participants with Corticosteroid-free Remission Measured in participants receiving corticosteroids at randomization of parent Study 20170104. Week 52
Secondary Number of Participants with Corticosteroid-free Remission Measured in participants receiving corticosteroids at randomization of parent Study 20170104. Week 104
Secondary Number of Participants with Combined Endoscopic and Histologic Remission at Week 52 Week 52
Secondary Number of Participants with Combined Endoscopic and Histologic Remission at Week 104 Week 104
Secondary Number of Participants with Symptomatic Remission at Week 52 Week 52
Secondary Number of Participants with Symptomatic Remission at Week 104 Week 104
Secondary Change from Baseline of Study 20170104 in Histological Score (Geboes) at Week 52 Baseline of Study 20170104 to Week 52 of Long Term Extension Study (up to approximately 104 weeks)
Secondary Change from Baseline of Study 20170104 in Histological Score (Geboes) at Week 104 Baseline of Study 20170104 to Week 104 of Long Term Extension Study (up to approximately 156 weeks)
See also
  Status Clinical Trial Phase
Recruiting NCT05702879 - Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success
Not yet recruiting NCT05953402 - A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring
Recruiting NCT05316584 - A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy N/A
Recruiting NCT03950232 - An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis Phase 3
Completed NCT03124121 - Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels Phase 4
Not yet recruiting NCT06100289 - A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease Phase 3
Withdrawn NCT04209556 - A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis Phase 2
Terminated NCT00061282 - Clotrimazole Enemas for Pouchitis in Children and Adults Phase 1/Phase 2
Recruiting NCT04398550 - SCD vs. Mediterranean Diet Therapy in Ulcerative Colitis N/A
Recruiting NCT04314375 - Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis Phase 4
Active, not recruiting NCT04857112 - Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis Phase 2
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Active, not recruiting NCT04033445 - A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis Phase 2/Phase 3
Recruiting NCT05428345 - A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
Active, not recruiting NCT06221995 - Energy Expenditure in Patients With Ulcerative Colitis Undergoing Surgery
Recruiting NCT04767984 - Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis Phase 2
Completed NCT02508012 - Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases N/A
Recruiting NCT06071312 - FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach Phase 1/Phase 2
Completed NCT03760003 - Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis Phase 2
Not yet recruiting NCT05539625 - Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative Colitis Phase 2